LRRFIP1 expression triggers platelet agglutination by enhancing αIIbβ3 expression

Yin,Xiang; Liu,Peng; Liu,Yao‑Yao; Liu,Ming‑Yong; Fan,Wei‑Li; Liu,Bai‑Yi; Zhao,Jian‑Hua

doi:10.3892/etm.2019.7571

LRRFIP1 expression triggers platelet agglutination by enhancing αIIbβ3 expression

Authors:
- Xiang Yin
- Peng Liu
- Yao‑Yao Liu
- Ming‑Yong Liu
- Wei‑Li Fan
- Bai‑Yi Liu
- Jian‑Hua Zhao
View Affiliations

Affiliations: Department of Spinal Surgery, Institute of Surgery Research, Daping Hospital, Army Medical University, Chongqing 400042, P.R. China
Published online on: May 10, 2019 https://doi.org/10.3892/etm.2019.7571
Pages: 269-277
Copyright: © Yin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Platelets primarily participate in hemostasis and antimicrobial host defense. The present study aimed to investigate the effects of leucine‑rich repeat flightless‑interacting protein‑1 (LRRFIP1) on platelet agglutination. The bacterial strain of LRRFIP1 was used to synthesize the recombinant protein and a mouse model of LRRFIP1 gene knockout was established. Platelets were isolated from the mice and divided into the different trial groups according to their treatment with collagen, thrombin receptor SFLLRN, anti‑wild‑type (w)LRRFIP1monoclonal antibodies and the model of LRRFIP1 gene knockout. The platelets were prepared and platelet agglutination was examined using platelet aggregation apparatus. The active αIIbβ3 integrin was examined by flow cytometry. The results revealed that the combined wLRRFIP1 protein was successfully expressed. wLRRFIP1 treatment significantly triggered platelet agglutination of collagen, thrombin and monoclonal antibody treated platelets. wLRRFIP1 knockout significantly decreased αIIbβ3 levels compared with the wild‑type. Platelet agglutination was also significantly inhibited in the LRRFIP1‑/‑mouse model compared with the wild‑type. LRRFIP1 knockout significantly decreased the αIIbβ3 levels in platelets undergoing convulxin treatment. In conclusion, LRRFIP1 treatment triggered platelet agglutination and LRRFIP1 gene knockout inhibited platelet agglutination. In addition, LRRFIP1 gene knockout significantly decreased the levels of αIIbβ3. This suggests that LRRFIP1 my be applied to patients in a clinical setting to trigger platelet agglutination in inflammatory diseases and atherothrombotic diseases.

View Figures

View References

1	Grozovsky R, Giannini S, Falet H and Hoffmeister KM: Regulating billions of blood platelets: Glycans and beyond. Blood. 126:1877–1884. 2015. View Article : Google Scholar : PubMed/NCBI
2	Hattori H and Ishihara M: Feasibility of improving platelet-rich plasma therapy by using chitosan with high platelet activation ability. Exp Ther Med. 13:1176–1180. 2017. View Article : Google Scholar : PubMed/NCBI
3	Ed Rainger G, Chimen M, Harrison MJ, Yates CM, Harrison P, Watson SP, Lordkipanidzé M and Nash GB: The role of platelets in the recruitment of leukocytes during vascular disease. Platelets. 26:507–520. 2015. View Article : Google Scholar : PubMed/NCBI
4	Gibbins JM: Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci. 117:3415–3425. 2004. View Article : Google Scholar : PubMed/NCBI
5	Grozovsky R, Giannini S, Falet H and Hoffmeister KM: Novel mechanisms of platelet clearance and thrombopoietin regulation. Curr Opin Hematol. 22:445–451. 2015. View Article : Google Scholar : PubMed/NCBI
6	Kurosawa Y, Nirengi S, Homma T, Esaki K, Ohta M, Clark JF and Hamaoka T: A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Sci Rep. 5:116012015. View Article : Google Scholar : PubMed/NCBI
7	Xie J, Ma J, Huang Q, Yue C and Pei F: Comparison of enoxaparin and rivaroxaban in balance of anti-fibrinolysis and anticoagulation following primary total knee replacement: A pilot study. Med Sci Monit. 23:704–711. 2017. View Article : Google Scholar : PubMed/NCBI
8	Chen Z, Chen B, Yao XQ, Gui BS, Ou Y and Ouyang JM: Anticoagulation of diethyl citrate and its comparison with sodium citrate in an animal model. Blood Purif. 33:30–36. 2012. View Article : Google Scholar : PubMed/NCBI
9	Yeung J, Tourdot BE, Fernandez-Perez P, Vesci J, Ren J, Smyrniotis CJ, Luci DK, Jadhav A, Simeonov A, Maloney DJ, et al: Platelet 12-LOX is essential for FcgammaRIIa-mediated platelet activation. Blood. 124:2271–2279. 2014. View Article : Google Scholar : PubMed/NCBI
10	Violi F and Pignatelli P: Platelet NOX, a novel target for anti-thrombotic treatment. Thromb Haemost. 111:817–823. 2014. View Article : Google Scholar : PubMed/NCBI
11	Dütting S, Bender M and Nieswandt B: Platelet GPVI. A target for antithrombotic therapy?! Trends Pharmacol Sci. 33:583–590. 2012. View Article : Google Scholar : PubMed/NCBI
12	Tsuji M, Ezumi Y, Arai M and Takayama H: A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem. 272:23528–23531. 1997. View Article : Google Scholar : PubMed/NCBI
13	Suzuki-Inoue K, Fuller GL, García A, Eble JA, Pöhlmann S, Inoue O, Gartner TK, Hughan SC, Pearce AC, Laing GD, et al: A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 107:542–549. 2006. View Article : Google Scholar : PubMed/NCBI
14	Rosenfeld SI, Looney RJ, Leddy JP, Phipps DC, Abraham GN and Anderson CL: Human platelet Fc receptor for immunoglobulin G. Identification as a 40,000-molecular-weight membrane protein shared by monocytes. J Clin Invest. 76:2317–2322. 1985. View Article : Google Scholar : PubMed/NCBI
15	Zhi H, Rauova L, Hayes V, Gao C, Boylan B, Newman DK, McKenzie SE, Cooley BC, Poncz M and Newman PJ: Cooperative integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo. Blood. 121:1858–1867. 2013. View Article : Google Scholar : PubMed/NCBI
16	Suriano AR, Sanford AN, Kim N, Oh M, Kennedy S, Henderson MJ, Dietzmann K and Sullivan KE: GCF2/LRRFIP1 represses tumor necrosis factor alpha expression. Mol Cell Biol. 25:9073–9081. 2005. View Article : Google Scholar : PubMed/NCBI
17	Santiago FS and Khachigian LM: Ets-1 stimulates platelet-derived growth factor A-chain gene transcription and vascular smooth muscle cell growth via cooperative interactions with Sp1. Circ Res. 95:479–487. 2004. View Article : Google Scholar : PubMed/NCBI
18	Goodall AH, Burns P, Salles I, Macaulay IC, Jones CI, Ardissino D, de Bono B, Bray SL, Deckmyn H, Dudbridge F, et al: Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood. 116:4646–4656. 2010. View Article : Google Scholar : PubMed/NCBI
19	Burns P, Gusnanto A, Macaulay IC, Rankin A, Tom B, Langford CF, Dudbridge F, Ouwehand WH and Watkins NA; Bloodomics Consortium, : Identification of variation in the platelet transcriptome associated with glycoprotein 6 haplotype. Platelets. 19:258–267. 2008. View Article : Google Scholar : PubMed/NCBI
20	Fong KS and de Couet HG: Novel proteins interacting with the leucine-rich repeat domain of human flightless-I identified by the yeast two-hybrid system. Genomics. 58:146–157. 1999. View Article : Google Scholar : PubMed/NCBI
21	Jones-Bolin S: Guidelines for the care and use of laboratory animals in biomedical research. Curr Protoc Pharmacol Appendix 4. Appendix 4B. 2012. View Article : Google Scholar
22	Dennis MB Jr: Humane endpoints for genetically engineered animal models. ILAR J. 41:94–98. 2000. View Article : Google Scholar : PubMed/NCBI
23	Langer HF, Choi EY, Zhou H, Schleicher R, Chung KJ, Tang Z, Gobel K, Bdeir K, Chatzigeorgiou A, Wong C, et al: Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res. 110:1202–1210. 2012. View Article : Google Scholar : PubMed/NCBI
24	Sorrentino S, Studt JD, Medalia O and Tanuj Sapra K: Roll, adhere, spread and contract: Structural mechanics of platelet function. Eur J Cell Biol. 94:129–138. 2015. View Article : Google Scholar : PubMed/NCBI
25	Ding C, Zhang J, Li R, Wang J, Hu Y, Chen Y, Li X and Xu Y: Investigation of standardized administration of anti-platelet drugs and its effect on the prognosis of patients with coronary heart disease. Exp Ther Med. 14:3207–3212. 2017. View Article : Google Scholar : PubMed/NCBI
26	Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al: Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 303:754–762. 2010. View Article : Google Scholar : PubMed/NCBI
27	Liu YT and Yin HL: Identification of the binding partners for flightless I, A novel protein bridging the leucine-rich repeat and the gelsolin superfamilies. J Biol Chem. 273:7920–7927. 1998. View Article : Google Scholar : PubMed/NCBI
28	Yin X, Wu S, Wang Z, Wang Y, Du Q and Wang A: Anti-thrombosis effect of LRRFIP1 shRNA lentivirus in a mouse model of deep vein thrombosis. Thromb Res. 132:127–131. 2013. View Article : Google Scholar : PubMed/NCBI
29	Bhoria P, Varma N, Malhotra P, Varma S and Luthra-Guptasarma M: Immunodiagnosis of platelet activation in immune thrombocytopenia through scFv antibodies cognate to activated IIb3 integrins. MAbs. 7:1212–1220. 2015. View Article : Google Scholar : PubMed/NCBI
30	Fullard JF: The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis. Curr Pharm Des. 10:1567–1576. 2004. View Article : Google Scholar : PubMed/NCBI
31	Bennett JS: Structure and function of the platelet integrin alphaIIbbeta3. J Clin Invest. 115:3363–3369. 2005. View Article : Google Scholar : PubMed/NCBI
32	Chen P, Sun CX and Liu JN: A novel anti-platelet monoclonal antibody (3C7) specific for the complex of integrin alpha IIb beta3 inhibits platelet aggregation and adhesion. J Biol Chem. 280:25403–25408. 2005. View Article : Google Scholar : PubMed/NCBI